CRISPR and Vertex Release Additional Data for Blood Disease Treatment

Shares of CRISPR are up more than 10% at 12:36 pm EST as the CRISPR-based treatment continues to help patients with transfusion-dependent beta thalassemia (TDT) and sickle cell disease (SCD). Vertex, which is much larger and less dependent on the development of CTX001, is up 3.3%, about the same as the S&P 500.